Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Jun 20, 2025; 15(2): 102897
Published online Jun 20, 2025. doi: 10.5493/wjem.v15.i2.102897
Published online Jun 20, 2025. doi: 10.5493/wjem.v15.i2.102897
Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models
Anna Terasawa, Department of Clinical Oncology, Akita University, Akita 010-8543, Japan
Kazuhiro Shimazu, Hiroyuki Shibata, Department of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
Hiroshi Nanjo, Department of Pathology, Akita University, Akita 010-8543, Japan
Masatomo Miura, Department of Pharmacokinetics, Graduate School of Medicine, Akita University, Akita, Japan
Author contributions: Terasawa A, Shimazu K, Shibata H designed and coordinated the study; Terasawa A, Shimazu K, Shibata H, Miura M, Shibata H performed the experiments, acquired and analyzed data; Terasawa A, Shimazu K, Nanjo H, Miura M, Shibata H interpreted the data; Terasawa A, Shibata H wrote the manuscript; all authors approved the final version of the article.
Supported by TAIHO Pharmaceutical, No. AS2023A000122715; and Nippon Kayaku, No. NKCS20230416001.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board at Akita University.
Institutional animal care and use committee statement: All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals. This study proposal received approval from the Research Ethics Committee at Akita University: No. b-1-0440.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hiroyuki Shibata, MD, PhD, Professor, Department of Clinical Oncology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita 010-8543, Japan. hiroyuki@med.akita-u.ac.jp
Received: November 1, 2024
Revised: December 31, 2024
Accepted: January 21, 2025
Published online: June 20, 2025
Processing time: 166 Days and 7.5 Hours
Revised: December 31, 2024
Accepted: January 21, 2025
Published online: June 20, 2025
Processing time: 166 Days and 7.5 Hours
Core Tip
Core Tip: Malignant meningiomas have a poor prognosis, but drug development is limited due to their rarity. The curcumin analog GO-Y030 showed approximately 10-16 times stronger inhibitory effects than curcumin on IOMM-Lee and HKBMM cell lines, in vitro. Intraperitoneal administration of GO-Y030 also significantly inhibited the growth of malignant meningiomas, IOMM-Lee inoculated in nude mouse models. GO-Y030 significantly inhibited hepatocyte growth factor, nuclear factor kappa B, and N-cadherin, which contribute to epithelial-mesenchymal transition.